Loading...
XNAS
INCY
Market cap11bUSD
Apr 09, Last price  
58.86USD
1D
3.32%
1Q
-19.51%
Jan 2017
-41.30%
Name

Incyte Corp

Chart & Performance

D1W1MN
P/E
349.25
P/S
2.69
EPS
0.17
Div Yield, %
—
Shrs. gr., 5y
-0.66%
Rev. gr., 5y
14.46%
Revenues
4.24b
+14.76%
7,846,00027,643,00034,440,0003,919,0009,265,000169,878,00094,455,000297,059,000354,947,000511,495,000753,751,0001,105,719,0001,536,216,0001,881,883,0002,158,759,0002,666,702,0002,986,267,0003,394,635,0003,695,649,0004,241,217,000
Net income
33m
-94.54%
-103,043,000-74,166,000-86,881,000-178,920,000-211,870,000-31,846,000-186,540,000-44,320,000-83,147,000-48,481,0006,531,000104,222,000-313,142,000109,493,000446,906,000-295,697,000948,581,000340,660,000597,599,00032,615,000
CFO
335m
-32.46%
-101,872,000-50,367,000-92,694,000-140,860,00012,358,00097,938,000-161,715,000-94,830,0009,180,00026,256,00086,536,000304,756,000-92,988,000336,227,000710,656,000-124,599,000749,488,000969,941,000496,487,000335,337,000
Earnings
Apr 28, 2025

Profile

Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Its clinical stage products include ruxolitinib, a steroid-refractory chronic graft-versus-host-diseases (GVHD); itacitinib, which is in Phase II/III clinical trial to treat naïve chronic GVHD; and pemigatinib for treating bladder cancer, cholangiocarcinoma, myeloproliferative syndrome, and tumor agnostic. In addition, the company engages in developing Parsaclisib, which is in Phase II clinical trial for follicular lymphoma, marginal zone lymphoma, and mantel cell lymphoma. Additionally, it develops Retifanlimab that is in Phase II clinical trials for MSI-high endometrial cancer, merkel cell carcinoma, and anal cancer, as well as in Phase II clinical trials for patients with non-small cell lung cancer. It has collaboration agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; Agenus Inc.; Calithera Biosciences, Inc; MacroGenics, Inc.; Merus N.V.; Syros Pharmaceuticals, Inc.; Innovent Biologics, Inc.; Zai Lab Limited; Cellenkos, Inc.; and Nimble Therapeutics, as well as clinical collaborations with MorphoSys AG and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. The company was incorporated in 1991 and is headquartered in Wilmington, Delaware.
URL
https://www.incyte.com/
IPO date
Dec 06, 1993
Employees
2,324
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
4,241,217
14.76%
3,695,649
8.87%
3,394,635
13.67%
Cost of revenue
4,161,073
3,043,894
2,795,073
Unusual Expense (Income)
NOPBT
80,144
651,755
599,562
NOPBT Margin
1.89%
17.64%
17.66%
Operating Taxes
284,015
236,616
188,456
Tax Rate
354.38%
36.30%
31.43%
NOPAT
(203,871)
415,139
411,106
Net income
32,615
-94.54%
597,599
75.42%
340,660
-64.09%
Dividends
Dividend yield
Proceeds from repurchase of equity
(2,004,790)
7,286
34,814
BB yield
13.79%
-0.05%
-0.19%
Debt
Debt current
4,419
9,125
11,374
Long-term debt
71,503
67,449
66,524
Deferred revenue
(42,562)
Other long-term liabilities
321,305
322,729
221,000
Net debt
(2,100,984)
(3,767,185)
(3,294,743)
Cash flow
Cash from operating activities
335,337
496,487
969,941
CAPEX
(86,263)
(47,486)
(77,833)
Cash from investing activities
157,517
(207,677)
(78,542)
Cash from financing activities
(2,021,547)
(20,033)
(794)
FCF
(221,037)
403,699
396,966
Balance
Cash
2,158,092
3,656,043
3,238,965
Long term investments
18,814
187,716
133,676
Excess cash
1,964,845
3,658,977
3,202,909
Stockholders' equity
(1,085,809)
173,715
(421,922)
Invested Capital
4,892,703
5,377,138
5,008,007
ROIC
7.99%
8.37%
ROCE
2.11%
11.74%
12.95%
EV
Common stock shares outstanding
210,530
225,928
223,958
Price
69.07
10.00%
62.79
-21.83%
80.32
9.43%
Market cap
14,541,307
2.50%
14,186,019
-21.14%
17,988,307
10.36%
EV
12,440,323
10,418,834
14,693,564
EBITDA
169,392
734,415
667,417
EV/EBITDA
73.44
14.19
22.02
Interest
2,280
2,551
2,666
Interest/NOPBT
2.84%
0.39%
0.44%